Ariely (adebrelimab) / Jiangsu Hengrui Pharma - LARVOL DELTA

SPRING: Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS (clinicaltrials.gov) - P2 | N=200 | Not yet recruiting | Sponsor: Peking University Shenzhen Hospital

Biomarker • New P2 trial • Oncology

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=762 | Not yet recruiting | Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

New P1 trial • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

SHR-8068 plus adebrelimab and bevacizumab for advanced hepatocellular carcinoma (aHCC): A phase 1b/2 study. (ASCO 2025) - P1/2 | "Clinical Trial Registration Number: NCT05444088 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Metastases • P1/2 data • Hepatocellular Cancer • Oncology • Solid Tumor

A phase II clinical study of adebrelimab and bevacizumab combined with cisplatin/carboplatin in triple-negative breast cancer patients with brain metastases. (ASCO 2025) - P2 | "Clinical Trial Registration Number: NCT04303988 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Clinical • P2 data • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

NEO-ERA-01: A multi-center, single-arm, phase II study with neoadjuvant therapy of HAIC (GEMOX) combined with adebrelimab and lenvatinib for resectable intrahepatic cholangiocarcinoma with high-risk recurrence factors. (ASCO 2025) - P2 | "Clinical Trial Registration Number: NCT06208462 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Clinical • P2 data • Biliary Cancer • Cholangiocarcinoma • Oncology • Solid Tumor

Phase II clinical study of the efficacy and safety of adebrelimab in combination with lenvatinib as second-line treatment for advanced intrahepatic cholangiocarcinoma. (ASCO 2025) - P2 | "Clinical Trial Registration Number: ChiCTR2300078869 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Clinical • Combination therapy • Metastases • P2 data • Biliary Cancer • Cholangiocarcinoma • Oncology • Solid Tumor

Adebrelimab Combined with Short-Course Radiotherapy and CAPOX as Total Neoadjuvant Therapy for pMMR Locally Advanced Rectal Cancer: Interim Results (ESMO-GI 2025) - No abstract available

Clinical • Metastases • pMMR • Colorectal Cancer • Oncology • Rectal Cancer • Solid Tumor

A prospective, single-arm, phase II trial of adebrelimab plus nab-paclitaxel and carboplatin in patients with unresectable advanced metastatic or recurrent thymic carcinomas. (ASCO 2025) - P2 | "Clinical Trial Registration Number: ChiCTR2300072705 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Clinical • Metastases • P2 data • Oncology • Solid Tumor • Thymic Carcinoma • Thymus Cancer

A phase 2, randomized, multicenter study of adjuvant adebrelimab plus capecitabine in resected cholangiocarcinoma with high-risk factors: ACHIEVE. (ASCO 2025) - P2 | "Clinical Trial Registration Number: NCT06607276 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Clinical • P2 data • Biliary Cancer • Cholangiocarcinoma • Oncology • Solid Tumor

Efficacy of adebrelimab with chidamide, gemcitabine, and S-1 in locally advanced or metastatic pancreatic cancer: A phase II study. (ASCO 2025) - P2 | "Clinical Trial Registration Number: NCT06584227 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Clinical • Metastases • P2 data • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor

SHR-A1811 plus adebrelimab in unresectable or metastatic triple-negative breast cancer: Results from a phase 1b/2 expansion cohort. (ASCO 2025) - P2 | "Clinical Trial Registration Number: NCT05353361 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Metastases • P1/2 data • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

A prospective, single-arm, phase II study of adebrelimab plus carboplatin and albumin-bound taxanol as neoadjuvant therapy in patients with resectable locally advanced head and neck squamous cell carcinoma. (ASCO 2025) - P2 | "Clinical Trial Registration Number: NCT06016413 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Clinical • Metastases • P2 data • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC) (clinicaltrials.gov) - P2 | N=60 | Not yet recruiting | Sponsor: Fudan University

New P2 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors (clinicaltrials.gov) - P2 | N=400 | Recruiting | Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

Adebrelimab plus apatinib for maintenance treatment of extensive-stage small cell lung cancer after first-line induction with adebrelimab plus chemotherapy (CLOG2402-ADAPT): a multi-center, single-arm, phase 2 clinical trial (ELCC 2025) - P=N/A, P2 | "The phase III ETER701 clinical trial demonstrated the survival benefits of adding anlotinib to benmelstobart and chemotherapy, but the risks of hemoptysis and occult blood test positive cannot be ignored. The primary endpoint is progression-free survival (PFS). The secondary endpoints include objective response rate, disease control rate, PFS2, duration of response, overall survival, and safety."

Clinical • P2 data • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC (clinicaltrials.gov) - P1/2 | N=400 | Recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard Treatment (clinicaltrials.gov) - P2 | N=40 | Active, not recruiting | Sponsor: Shanghai Zhongshan Hospital | Recruiting ➔ Active, not recruiting | Trial completion date: Sep 2024 ➔ Sep 2025

Enrollment closed • Trial completion date • Biliary Cancer • Cholangiocarcinoma • Hepatology • Oncology • Solid Tumor • CTLA4

SHR-A1811-Ib/II-205: Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer (clinicaltrials.gov) - P2 | N=76 | Active, not recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | N=258 ➔ 76 | Trial primary completion date: Jul 2026 ➔ Apr 2025 | Recruiting ➔ Active, not recruiting

Enrollment change • Enrollment closed • Trial primary completion date • Esophageal Cancer • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • HER-2

ACADEMY: A Trial of Apatinib and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable ICC (clinicaltrials.gov) - P2 | N=38 | Recruiting | Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

New P2 trial • Biliary Cancer • Cholangiocarcinoma • Oncology • Solid Tumor

Neoadjuvant SNF Precision Therapy Phase III (clinicaltrials.gov) - P3 | N=404 | Not yet recruiting | Sponsor: Fudan University

New P3 trial • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor

Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping (clinicaltrials.gov) - P2 | N=140 | Not yet recruiting | Sponsor: China Medical University, China

New P2 trial • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor

Phase II clinical study of adebrelimab plus apatinib and SOX regimen for conversion therapy of advanced gastric or gastroesophageal junction adenocarcinoma (ChiCTR) - P2 | N=49 | Recruiting | Sponsor: Beijing Friendship Hospital, Capital Medical University; Beijing Friendship Hospital, Capital Medical University

New P2 trial • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor

ICT-HCC: Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - P=N/A | N=300 | Not yet recruiting | Sponsor: Nanjing Tianyinshan Hospital

New trial • Hepatocellular Cancer • Oncology • Solid Tumor

A single arm, exploratory study on the combination of Adebrelimab and Apatinib as adjuvant therapy for hepatocellular carcinoma patients at high risk of recurrence after resection surgery (ChiCTR) - P4 | N=30 | Not yet recruiting | Sponsor: Qilu Hospital of Shandong University; Qilu Hospital of Shandong University

New P4 trial • Hepatocellular Cancer • Oncology • Solid Tumor

Adebrelimab combined with apatinib and chemotherapy in NSCLC treated with first-line PD-1 inhibitor therapy:a prospective, single-center, single-arm clinical study (ChiCTR) - P4 | N=30 | Not yet recruiting | Sponsor: Affiliated Hospital of Jiangnan University; Affiliated Hospital of Jiangnan University

New P4 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • EGFR • ROS1